About Mark Sard
Form D filings for Lirum Therapeutics in 2023 list Mark Sard as director.
Mark Sard reports to the SEC as a director of 1 public company: Stemline Therapeutics (STML).
Mark Sard first appears on SEC filings in 2018.
Experience
This experience comes from SEC filings. The years are when the filings name Mark Sard in the role, so the role may have started earlier or lasted longer.
SI
Stemline Therapeutics Inc.
Director
2018 – 2020 · Public company (STML)
Key Colleagues at Startups
The people Mark Sard works with at each company, as listed on that company's latest Form D.
Lirum Therapeutics, Inc. · Form D, Feb 23, 2023